Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

Posted by ABMN Staff on Mar 29th, 2025

StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Free Report) in a research report sent to investors on Friday. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a research note on Monday, March 10th.

Check Out Our Latest Stock Analysis on AEMD

Aethlon Medical Stock Performance

AEMD opened at $0.37 on Friday. The company has a market capitalization of $5.30 million, a PE ratio of -0.23 and a beta of 1.80. The stock’s fifty day moving average is $0.56 and its 200-day moving average is $0.50. Aethlon Medical has a one year low of $0.24 and a one year high of $1.79.

Aethlon Medical (NASDAQ:AEMD – Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.09. On average, equities research analysts forecast that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Aethlon Medical

Hedge funds have recently modified their holdings of the stock. Boothbay Fund Management LLC acquired a new stake in Aethlon Medical during the 4th quarter worth about $186,000. Virtu Financial LLC purchased a new position in shares of Aethlon Medical in the fourth quarter worth approximately $81,000. Sassicaia Capital Advisers LLC purchased a new position in shares of Aethlon Medical in the fourth quarter worth approximately $31,000. Allegiance Financial Group Advisory Services LLC acquired a new stake in shares of Aethlon Medical during the fourth quarter valued at approximately $26,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Aethlon Medical in the 4th quarter valued at approximately $25,000. 1.99% of the stock is owned by hedge funds and other institutional investors.

About Aethlon Medical

(Get Free Report)

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.